K Klingels1,2, A G Mayhew3, E S Mazzone4, T Duong5, V Decostre6, U Werlauff7, E Vroom8, E Mercuri4, N M Goemans9. 1. Department of Rehabilitation Sciences, KU Leuven, Leuven, Belgium. 2. Rehabilitation Research Center (REVAL), Biomed, Hasselt University, Diepenbeek, Belgium. 3. John Walton Muscular Dystrophy Research Centre, Institute of Genetic Medicine, Newcastle upon Tyne, UK. 4. Department of Paediatric Neurology, Catholic University, Rome, Italy. 5. Department of Neurology, Stanford University School of Medicine, Stanford, CA, USA. 6. Institut de Myologie, GH Pitié Salpêtrière, Paris, France. 7. Danish National Rehabilitation Center for Neuromuscular Diseases, Aarhus, Denmark. 8. Duchenne Parent Project, Veenendaal, the Netherlands. 9. Department of Child Neurology, University Hospitals Leuven, Leuven, Belgium.
Abstract
AIM: To develop a patient-reported outcome measure (PROM) assessing upper limb function related to activities of daily living (ADL) that cannot be observed in a clinical setting, specifically for patients with Duchenne muscular dystrophy (DMD) across a wide age range, applicable in the different stages of the disease. METHOD: The developmental process was based on US Food and Drug Administration guidelines. This included item generation from a systematic review of existing tools and expert opinion on task difficulty and relevance, involving individuals with DMD. Cultural aspects affecting ADL were taken into consideration to make this tool applicable to the broad DMD community. Items were selected in relation to a conceptual framework reflecting disease progression covering the full range of upper limb function across different ADL domains. RESULTS: After pilot testing and iterative Rasch analyses, redundant or clinically irrelevant items were removed. The final questionnaire consists of 32 items covering four domains of ADL (food, self-care, household and environment, leisure and communication). Test-retest reliability was excellent. INTERPRETATION: A DMD-specific upper limb PROM was developed on the basis of clinical relevance and psychometric robustness. Its main purpose is to document the patient self-reported natural history of DMD and assess the efficacy of interventions.
AIM: To develop a patient-reported outcome measure (PROM) assessing upper limb function related to activities of daily living (ADL) that cannot be observed in a clinical setting, specifically for patients with Duchenne muscular dystrophy (DMD) across a wide age range, applicable in the different stages of the disease. METHOD: The developmental process was based on US Food and Drug Administration guidelines. This included item generation from a systematic review of existing tools and expert opinion on task difficulty and relevance, involving individuals with DMD. Cultural aspects affecting ADL were taken into consideration to make this tool applicable to the broad DMD community. Items were selected in relation to a conceptual framework reflecting disease progression covering the full range of upper limb function across different ADL domains. RESULTS: After pilot testing and iterative Rasch analyses, redundant or clinically irrelevant items were removed. The final questionnaire consists of 32 items covering four domains of ADL (food, self-care, household and environment, leisure and communication). Test-retest reliability was excellent. INTERPRETATION: A DMD-specific upper limb PROM was developed on the basis of clinical relevance and psychometric robustness. Its main purpose is to document the patient self-reported natural history of DMD and assess the efficacy of interventions.
Authors: R R van Tol; E van Zwietering; J Kleijnen; J Melenhorst; L P S Stassen; C D Dirksen; S O Breukink Journal: Int J Colorectal Dis Date: 2018-04-22 Impact factor: 2.571
Authors: Michelle K White; Mindy Leffler; Kaitlin Rychlec; Chris Jones; Christine McSherry; Linsey Walker; Mark Kosinski Journal: Qual Life Res Date: 2019-07-13 Impact factor: 4.147
Authors: Karin J Naarding; Menno van der Holst; Erik W van Zwet; Nienke M van de Velde; Imelda J M de Groot; Jan J G M Verschuuren; Hermien E Kan; Erik H Niks Journal: Neurology Date: 2021-09-07 Impact factor: 9.910
Authors: Maaike van Putten; Annemieke Aartsma-Rus; Miranda D Grounds; Joe N Kornegay; Anna Mayhew; Thomas H Gillingwater; Shin'ichi Takeda; Markus A Rüegg; Annamaria De Luca; Kanneboyina Nagaraju; Raffaella Willmann Journal: J Neuromuscul Dis Date: 2018